Population Physiologically Based Pharmacokinetic Modeling for the Human Lactational Transfer of PCB-153 with Consideration of Worldwide Human Biomonitoring Results
2008

Modeling PCB-153 Transfer in Breast Milk

publication Evidence: moderate

Author Information

Author(s): Laurel E. Redding, Michael D. Sohn, Thomas E. McKone, Jein-Wen Chen, Shu-Li Wang, Dennis P. H. Hsieh, Raymond S.H. Yang

Primary Institution: National Health Research Institutes, Taiwan

Hypothesis

How can we effectively use human biomonitoring data on PCB-153 levels in breast milk?

Conclusion

The model successfully describes the range of possible PCB-153 dispositions in maternal milk, suggesting a promising option for back-estimating doses for various populations.

Supporting Evidence

  • PCB-153 is the most prevalent PCB congener detected in human tissue.
  • The model predictions of PCB-153 in breast milk align with human biomonitoring data.
  • Reverse dosimetry modeling suggests high PCB-153 levels in Canadian Inuits.

Takeaway

This study created a model to understand how PCB-153, a harmful chemical, moves from mothers to their breast milk, helping us see how much of it babies might get.

Methodology

The study developed a physiologically based pharmacokinetic model using data from Taiwan and literature to predict PCB-153 transfer via lactation.

Limitations

The model did not conduct parameter estimation and simplified some physiological aspects.

Participant Demographics

The model focused on women of childbearing age, specifically around 25 years old.

Digital Object Identifier (DOI)

10.1289/ehp.11519

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication